You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The organizations noted in a letter to HHS and FDA that they "believe the agency's actions may in fact inflict greater harm on patients and impede innovation."
The firm said that UHC will cover the test for patients with major depressive disorder or anxiety who have failed to respond to one or more treatments.
The Elisabeth Severance Prentiss Foundation gift will expand research into the use of saliva to monitor lithium levels in patients with bipolar and other disorders.
While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.
The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.
The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.
The company has recently launched its first diagnostic test on the market and is developing a second, which is currently in clinical trials.